## 1 Usefulness of real-time RT-PCR to understand the kinetics of

# 2 SARS-CoV-2 in blood: a prospective study

3 Author Names and Affiliations:

| 4      | Nelly Daniela Zurita-Cruz PharmD <sup>1</sup> , Alexandra Martín-Ramírez PhD. <sup>1*</sup> , Diego Aníbal          |
|--------|---|
| 5      | Rodríguez-Serrano MD. <sup>2</sup> , Isidoro González-Álvaro MD., PhD <sup>3</sup> , Emilia Roy-Vallejo             |
| 6      | MD. <sup>4</sup> , Rafael De la Cámara MD. <sup>5</sup> , Leticia Fontán García-Rodrigo PharmD <sup>1</sup> , Laura |
| 7      | Cardeñoso Domingo PhD <sup>1</sup> .  |
| 8<br>9 | <ol> <li>Department of Clinical Microbiology. Hospital Universitario de la Princesa, Madrid,<br/>Spain.</li> </ol>  |
| 10     | 2. Intensive Care Department, Hospital Universitario de la Princesa, Madrid, Spain.                                 |
| 11     | 3. Rheumatology Department, Hospital Universitario de la Princesa, Madrid, Spain.                                   |
| 12     | 4. Internal Medicine Department, Hospital Universitario de la Princesa, Madrid                                      |
| 13     | 5. Hematology Department, Hospital Universitario de la Princesa, Madrid   |
| 14     | Corresponding author:   |
| 15     | Nelly Daniela Zurita-Cruz PharmD.   |
| 16     | Departament of Clinical Microbiology. Hospital La Princesa Madrid   |
| 17     | C/Diego de León 62  |
| 18     | 28006 Madrid  |
| 19     | Spain   |
| 20     | Email: <u>nellydaniela.zurita@salud.madrid.org</u>  |
| 21     | Phone:+34615449741  |

22 Word count: 2428 words. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 23 Highlights

| 24 | • Commercial RT-PCR techniques could be used to monitor SARS-CoV-2 viremia                   |
|----|--|
| 25 | kinetics.  |
| 26 | • SARS-CoV-2 persistent viremia is related with poor outcome in COVID-19 patient.            |
| 27 | • SARS-Cov-2 viremia kinetics could be used as a biomarker of poor prognosis.                |
| 28 | • Plasma samples are the best choice for analysis of SARS-CoV-2 viremia kinetics.            |
| 29 |  |
| 30 | ABSTRACT   |
| 31 | Background   |
| 32 | SARS-CoV-2 viral load and kinetics assessed in serial blood samples from hospitalised        |
| 33 | COVID-19 patients by RT-PCR are poorly understood.   |
| 34 | Methods  |
| 35 | We conducted an observational, prospective case series study in hospitalised COVID-19        |
| 36 | patients. Clinical outcome data (Intensive Care Unit admission and mortality) were           |
| 37 | collected from all patients until discharge. Viremia was determined longitudinally during    |
| 38 | hospitalisation, in plasma and serum samples using two commercial and standardised RT-       |
| 39 | PCR techniques approved for use in diagnosis of SARS-CoV-2. Viral load (copies/mL and        |
| 40 | log10) was determined with quantitative TaqPath™COVID-19 test.                               |
| 41 | Results  |
| 42 | SARS-CoV-2 viremia was studied in 57 hospitalised COVID-19 patients. Persistent viremia      |
| 43 | (PV) was defined as two or more quantifiable viral loads detected in blood samples           |
| 44 | (plasma/serum) during hospitalisation. PV was detected in 16 (28%) patients. All of them,    |
| 45 | except for one who rapidly progressed to death, cleared viremia during hospitalisation. Poor |
| 46 | clinical outcome occurred in 62.5% of patients with PV, while none of the negative patients  |

| 47 | or those with sporadic viremia presented this outcome (p<0.0001). Viral load was           |
|----|--|
| 48 | significantly higher in patients with PV than in those with Sporadic Viremia (p<0.05).     |
| 49 | Patients presented PV for a short period of time: median time from admission was 5 days    |
| 50 | (Range=2-12) and 4.5 days (Range=2-8) for plasma and serum samples, respectively.          |
| 51 | Similar results were obtained with all RT-PCR assays for both types of samples.            |
| 52 | Conclusions  |
| 53 | Detection of persistent SARS-CoV-2 viremia, by real time RT-PCR, expressed as viral load   |
| 54 | over time, could allow identifying hospitalised COVID-19 patients at risk of poor clinical |
| 55 | outcome.   |
| 56 |  |
| 57 | Keywords   |
| 58 | SARS-CoV-2; Blood Viral-load; Viremia-Kinetics; rRT-PCR; Intensive Care Unit;              |
| 59 | Mortality.   |
| 60 |  |

## 62 INTRODUCTION

63 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first described in
64 December 2019 in Wuhan, China (1). As of 19th of January 2022, 5,542,359 deaths were reported
65 to WHO(2).

66 While most COVID-19 patients present mild disease, others develop a severe disease (3). 67 Identifying patients at risk of developing severe COVID-19 is an unmet need to improve the 68 management of these patients and prevent morbidity and mortality. Some risk factors of poor 69 prognosis, such as elevated concentrations of interleukin (IL)-6, contribute to risk stratification 70 of COVID-19 patients (4–6).

Detection of SARS-CoV-2 RNA by real-time reverse transcription polymerase chain reaction
(RT-PCR) in nasopharyngeal swabs is the gold standard for COVID-19 diagnosis (7). However,
no consistent association has been reported between the viral load in these samples and disease
severity (8).

Recently, detection of SARS-CoV-2 RNA in blood samples (viremia) has been considered as a potential predictor of poor prognosis, due to its association with rapid deterioration and death (9–13). Nevertheless, there is a lack of reports analysing viral load quantification over time in sequential samples, which could allow understanding viremia kinetics and its relationship with the patient clinical outcome.

The objectives of this prospective study were to analyse the kinetics of SARS-CoV-2 viremia, by qualitative and quantitative RT-PCR methods using standardised commercial reagents in sequential samples collected longitudinally from COVID-19 patients during hospital admission, and to determine its relationship with disease clinical course.

#### 85 MATERIAL AND METHODS

#### 86 <u>Study design and patients</u>

87 This is a prospective longitudinal case series study, conducted at Hospital Universitario de La 88 Princesa, Madrid (Spain), from November 2020 to January 2021. Fifty-seven consecutively 89 admitted patients with COVID-19 diagnosed by RT-PCR from nasopharyngeal swabs were 90 included. All patients gave their informed consent, and the research protocol was approved by the 91 Institutional Ethics Review Board (register number 4267). We followed guidance from The 92 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) standards for 93 observational research, and those of the Updated List of Essential Items for Reporting Diagnostic 94 Accuracy Studies (STARD) (14).

#### 95 Data collection and definitions

96 In addition to sociodemographic variables, clinical characteristics and outcome variables 97 (Intensive Care Unit [ICU] admission and mortality during hospitalisation) were collected. "Poor 98 Outcome" was considered when the patient had at least one of the two clinical variables described 99 above. Other relevant variables collected were symptom onset, hospital admission, hospital 100 discharge, death and sample collection dates. All data collected was entered in an anonymized 101 database with access only to the research team.

#### 102 Sample collection

First, a blood sample (serum and plasma) was collected within the first 24-36 hours upon
admission; subsequently, additional blood samples were collected every 48-72 hours during the
first week. Later, samples were collected twice a week until discharge. Samples were frozen at 80°C until RT-PCR performance.

#### 107 **Qualitative RT-PCR Methods**

All blood samples were assessed by two qualitative RT-PCR methods: Cobas®SARS-CoV-2
Test, Roche Diagnostics (cobas®-test), an automated method for SARS-CoV-2 detection; and

TaqPath<sup>™</sup>COVID-19 CE IVD RT-PCR Kit, Thermo Fisher Scientific (TaqPath<sup>™</sup>-test),
according to manufacturers' indications (details are shown in supplementary material). For
qualitative detection, samples were assessed in duplicate by TaqPath<sup>™</sup>-test and only once by
cobas®-test due to scarce volume.

#### 114 Quantification of SARS-CoV-2 viral load

115 Quantitative RT-PCR to determine viral load (qTaqPath-test) was performed using TaqPath<sup>TM</sup>test reagents in a QuantStudio<sup>™</sup> 5 Real Time PCR System (Applied Biosystems). Plasma and 116 117 serum samples were analysed in duplicate. Viral load quantification of serum and plasma samples 118 was obtained by plotting Ct values through the standard curve obtained using the QuantStudio<sup>™</sup> 119 Design and Analysis software version 2.4.3 (Applied Biosystems, USA) and according to 120 Thermocycler manufacturer specifications (15). Detailed description of standard curve 121 determination is shown in supplementary material. Samples were considered quantifiable when 122 mean Ct in the duplicate test for each gene was  $\leq$ 37 and standard deviation (SD) was <0.5. All 123 results not fulfilling these criteria and/or those with detection in only one duplicate, were 124 considered positive, but not quantifiable. To estimate a value for quantification limit, median of 125 all non-quantifiable values was calculated, obtaining 17.75 copies/mL for serum samples and 126 14.89 copies/mL for plasma samples. For the genes that met quantification criteria, mean quantity 127 was calculated from the duplicates, expressed as copies/mL and logarithm with base  $10(\log_{10})$ . Two positive controls (corresponding to 20,000 and 200 copies) and two negative controls were 128 129 added in each run in duplicate.

Moreover, we studied the number of genes (N, S or ORF) that were amplified in each plasma
sample tested by q-RT-PCR, as an indication of the association of viremia with the presence of
virions.

#### 133 Kinetics of SARS-CoV-2 in blood

The presence of SARS-CoV-2 RNA was detected by qualitative RT-PCR methods and viral load
was determined by qTaqPath-test in plasma and serum of each patient collected throughout the

- 136 follow-up. To analyse viremia kinetics, time course curves were obtained plotting viral load
- 137 change over time. Specific patterns of viral load change were identified and their relationship with
- 138 clinical evolution was analysed.
- 139 Statistical analysis is detailed in supplementary methods.

#### 140 **RESULTS**

#### 141 <u>Characteristics of the study population</u>

- 142 Fifty-seven patients consecutively admitted to our hospital were included in this study (Figure 1).
- 143 A median of 4 samples per patient (R=2-18) was collected. Median age was 64 years (R=31-94
- 144 years) and 61.4% were male. During hospital admission, 8 (14.0%) patients required ICU
- admission (median age 59.5 years; R=52-76 years; 87.5% male); and 5 (9%) died during
- hospitalisation (median age 76; R=59-86 years; 80% male). Some patients presented more than
- 147 one clinical condition. Patients included in the Poor Outcome group (n=10; 17.5%) had a median
- 148 age of 60.5 years; R=52-86 years, 85.7% were male.

## 149 Analysis of samples and RT-PCR techniques

- 150 A total of 598 samples (298 serum and 300 plasma samples) were assessed (Figure 1).
- 151



**Figure 1**: STROBE flow chart of the study including participation, sample collection and tests.

154

- 155 Qualitative detection obtained by  $cobas \mathbb{R}$  and  $TaqPath^{TM}$  tests showed a similar concordance
- 156 ( $\kappa$ =0.613 and  $\kappa$ =0.604, respectively) for both types of samples. However, both tests showed
- statistically significant higher positive detection in plasma samples (Table 1).
- **Table 1.** Agreement of viremia qualitative detection in serum and plasma samples according toRT-PCR technique.

|                         | cobas®-t                    | est (n=298)                 | TaqPath <sup>™</sup> -test (n=300) |                             |  |  |  |
|-------------------------|-----------------------------|-----------------------------|------------------------------------|-----------------------------|--|--|--|
| -                       | Plasma<br>Positive n<br>(%) | Plasma<br>Negative n<br>(%) | Plasma<br>Positive n (%)           | Plasma<br>Negative n<br>(%) |  |  |  |
| Serum Positive n (%)    | 75 (25.2)                   | 17 (6)                      | 76 (25.3)                          | 13 (4.6)                    |  |  |  |
| Serum Negative n<br>(%) | 35 (11.7)                   | 171 (57.8)                  | 41 (13.3)                          | 170 (56.7)                  |  |  |  |
| Agreement               | 82                          | 2.9%                        | 82%                                |                             |  |  |  |
| Kappa coefficient       | 0.                          | 613                         | 0.604                              |                             |  |  |  |
| p value                 | <0.                         | 0001                        | <0.0001                            |                             |  |  |  |

160

Mean Ct values obtained from plasma and serum by TaqPath<sup>TM</sup>-test (33.99±2.05 and 34.21±1.94,
respectively) and those obtained by cobas®-test (35.34±2.12 and 35.16±2.33, respectively) did
not show significant differences (p>0.5). Pearson correlation analysis of mean Ct showed
correlation coefficients (r) of 0.86 and 0.76 for plasma and serum samples, respectively (Figure
2). Results of the correlation of Ct obtained by both techniques in serum samples are consistent
with findings described in our previous series(16).



168

169 Figure 2: Scatter plot of mean Ct obtained by Taqpath<sup>™</sup> and cobas® RT-PCR tests in plasma
170 (a) and serum (b). Correlation between results was analysed by Pearson correlation (r=0.86 and
171 0.76, respectively. P<0.0001 for both techniques).</li>

172

## 173 Analysis of SARS-CoV-2 viral loads

Viral load could be quantified with qTaqPath-test in 50 plasma and 41 serum samples. Median viral load was 462.88 copies/mL (R=37.26-21,277) for plasma, and 370 copies/mL (R=29.42-15,257) for serum samples. Viral load expressed in  $log_{10}$  showed a normal distribution. Mean value of viral load in plasma was  $2.65\pm0.63$   $log_{10}$  and  $2.6\pm0.58$   $log_{10}$  for serum samples. No statistically significant differences were found between both types of samples (p=0.65). Furthermore, correlation analysis of viral load obtained from plasma and serum showed a Pearson correlation coefficient r=0.89 (Figure 3).



Figure 3: Comparison of viral load in plasma and serum samples. Viral loads were determined
by qTaqPath-test. Differences between plasma and serum were analysed by Student's t test
(p=0.65) (a). Correlation between data was evaluated by Pearson correlation coefficient (r=0.89;
p<0.0001) (b).</li>

187

## 188 Detection of SARS-CoV-2 genes in plasma samples

- 189 Detection of SARS-CoV-2 genes in plasma by TaqPath<sup>™</sup> Kit showed that at least two assay
- targets could be detected in 79% of the patients: all 3 targets were detected in 64.3%, 2 targets in
- 191 14,3% and only the N gene in 21.4% of the cases. (Figure 4).



192



194

#### 195 Kinetics of SARS-CoV-2 viremia in hospitalised patients

Viremia analysis over time was performed in consecutive plasma and serum samples of individual
patients (n=57) through the qualitative methods, cobas® and TaqPath<sup>TM</sup> tests, and viral load was
assessed using qTaqPath-test. Three different viremia patterns were identified: i) Persistent
Viremia (PV), viremia was detected in two or more consecutive determinations, n=16 (28%); ii)

Sporadic Viremia (SV), viremia was only detected in isolated samples, n=34 (60%); and, iii)
Negative Viremia (NV), viremia was not detected in any of the samples during hospitalisation,
n=7 (12%).

Patients presented PV for a short period of time: median time was 5 days (Range=2-12) for plasma
samples and 4.5 days (Range=2-8) for serum. Viremia clearance occurred spontaneously in PV
patients during hospitalisation, except for one patient who progressed rapidly to death.

206 Analysis of viral load in consecutive samples of all patients with PV (n=16) showed different

trends. Nine (56.2%) patients showed a parabolic curve, with an initial increase of viral load
followed by a decrease. Six (37.5%) patients, 5 of them admitted to ICU, showed a decreasing

209 viral load curve. Conversely, one patient (6.3%) showed increasing viral load until decease.

210 (Figure 5)

211



Figure 5. Viral load kinetics curves throughout hospitalisation in plasma from patients with
Persistent Viremia. Clinical characteristics defining poor outcome are included within the
graphics for each patient. ICU: intensive care unit.

To further characterise the kinetics of SARS-CoV-2 in the blood of patients with PV, both viremias assessed by the 2 qualitative techniques (expressed a Ct) and viral load assessed by the q-TaqPath test (expressed as copies/mL) were determined in plasma and serum samples. Kinetics

| 220 | curves represent the change of these parameters in individual PV patients during hospitalisation |
|-----|--|
| 221 | for the qualitative (Figure 6A) and quantitative (Figure 6B) determinations. Curves obtained for |
| 222 | each individual patient showed similar kinetic behaviour regardless of the technique or the type |
| 223 | of sample used for the analysis. These results suggest that PV could be monitored using plasma   |
| 224 | or serum samples and both, qualitative and quantitative RT-PCR methods.                          |
| 225 |  |



**Figure 6.** Analysis of SARS-CoV-2 viremia kinetics assessed by different RT-PCR methods in

227



patients, followed by their clinical outcome (ICU: Intensive Care Unit admission; M: Death
during hospital admission). The curves show the kinetics of viremia determined by the
TaqPath<sup>TM</sup>-test and cobas®-test, expressed as Ct values (A), and the q-TaqPath test, expressed in
copies/mL (B).

234

#### 235 Relationship of Persistent Viremia with clinical outcome and viral load in blood

Analysis of viral load in consecutive samples over time and its relationship with clinical outcome showed that 100% of those patients with Poor Outcome (ICU admission and/or death) during hospitalisation (N=10) presented PV, whereas none of those patients with SV and NV presented a Poor Outcome and all of them were discharged. Although 6 PV patients did not present any characteristic of poor clinical outcome, those patients represented only the 13% of all patients without Poor Outcome (N=47), that is, poor clinical outcome was significantly associated with PV compared to no PV (p < 0.0001), as shown in Figure 7.



Figure 7. Relationship of Persistent Viremia with clinical outcome. Distribution of patients according to the presence or absence of Persistent Viremia is shown. The comparison between both groups was analysed with the  $\chi^2$  test.

247

No difference was detected in age (p=0.2) or sex (p=0.4) between patients with different viremia
patterns.

The viral load had a normal distribution when it was expressed as  $log_{10}$ . Regarding viral load in patients with different viremia patterns, SV patients showed lower viral loads than PV. Median viral loads for SV were 77.3 copies/mL (IQR= 37.3-77.3; mean=  $1.82\pm0.22$  log<sub>10</sub>) and 59.4 copies/mL (IQR=29.4-59.4; mean= $1.71\pm0.34$  log<sub>10</sub>) for plasma and serum, respectively, whereas for PV median viral load was 558 copies/mL (IQR= 170.3-1145.4; mean=  $2.71\pm0.61$  log<sub>10</sub>) for plasma and 370.4 copies/mL (IQR=180.92-1233.6; mean= $2.57\pm0.55$  log<sub>10</sub>) for serum. Viral load was significantly higher for PV compared to SV for both types of samples (Figure 8).

257



258

Figure 8. Viral load is significantly higher in patients with persistent viremia than those with sporadic viremia in serum and plasma samples. The viral load expressed as log<sub>10</sub> showed a normal distribution, so the difference of viral loads between both groups was analysed by Student's t test.

263

## 264 DISCUSSION

The hypothesis of this study was that detectable SARS-CoV-2 viremia in successive samples over time (persistent viremia) could identify hospitalised COVID-19 patients with high risk of poor clinical outcome. To verify this, we studied methods for qualitative detection of SARS-CoV-2 RNA and for quantification of viral load in plasma and serum, using commercially available RT-PCR kits, marked with CE and FDA authorisation. In addition, the association of viremia evolution with patient outcome was also evaluated.

Regarding the relationship between disease severity and the pattern of viremia kinetics, our results
showed that all patients with ICU admission and/or death during hospitalisation had PV, while
none of the patients with SV or NV had poor clinical outcome in this cohort. This supports our
hypothesis that patients with PV are more likely to have a poor clinical outcome, in agreement
with other authors. (17-23)

276

277 The graphical representation of viremia kinetics patterns in patients with PV, assessed by two 278 qualitative and one quantitative RT-PCR methods showed similar kinetic patterns regardless of 279 the use of different reagents and RT-PCR platforms. This analysis suggests that the dynamics of 280 viremia in longitudinal samples correlates with the presence of SARS-CoV-2 in blood and is 281 reproducible. However, some discrepancy values were detected in isolated cases where the Ct 282 value or viral load was lower than those in the paired sample from the same blood extraction 283 (plasma vs. serum). We hypothesised that those discrepancies could be due to a loss of sample 284 integrity.(24) However, the fact that different techniques can be used to analyse the kinetics of 285 the SARS-CoV-2 viremia increases the versatility of this determination when it comes to its implementation in clinical microbiology laboratories. 286

Our previous results suggested that the Ct value is a good approximation for the stratification of severely ill patients(13). However, the variation due to the sample type and handling, the

technique used, and the intrinsic variability of RT-PCR makes it necessary to develop a standardised method to obtain more reproducible results(25). Even in this series, both assays detected a higher number of positives in plasma than in serum. In this sense, it is well known that the quantification of viral load in plasma has been standardised in other pathologies associated to viral infections such as HIV, HCV, HBV, CMV(26–29), and provides a more precise and reliable monitoring of viremia than Ct values. For this reason, we propose the use of SARS-CoV-2 viral load from plasma samples for the analysis of viremia kinetics.

296 Different authors have quantified viremia using new technologies such as Droplet Digital PCR 297 (18, 31) using internally developed methods with primer design (17), or ultrasensitive quantitative 298 RT-PCR(32). In this context, the objective of this work was to assess the usefulness of a 299 quantification method using RT-PCR to monitor SARS-CoV-2 viral load in hospitalised COVID-300 19 patients. We used commercial and standardised reagents with CE and FDA marking for 301 authorisation, making a standard curve and taking advantage of the options offered by the 302 QuantStudio 5 thermal cycler interpretation software. Taken all together, these characteristics 303 provide a robust and reproducible quantification method that allows monitoring viremia in 304 hospitalised COVID-19 patients. Also, we agree with other authors on the need to develop 305 standardised techniques for quantifying viral load in blood, with FDA or CE approval, that could 306 contribute to improve the management of patients with COVID-19(17, 21).

The detection of SARS-CoV-2 RNA in blood has been called RNAemia by some authors (24, 30, 31). However, we refer to this determination as viremia since, in almost 80% of the samples studied in this study, 2 or 3 SARS-CoV-2 genes were detected; the presence of these genes could be correlated with the presence of viral particles (32, 33). In addition, detection of RNA in successive blood samples would indicate the presence of the virus.

The present study has certain limitations. First, the number of patients included in the study was
moderate (57 patients). Second, although two RT-PCR techniques were performed, only the
TapPath<sup>TM</sup> test allowed us to quantify the viral load (in copies/ml and log<sub>10</sub> viral load).

| 315 | In summary, we conclude that persistent SARS-CoV-2 viremia in blood samples may be                |
|-----|---|
| 316 | potentially used as indicator of poor prognosis in hospitalised COVID-19 patients. Both           |
| 317 | qualitative and quantitative RT-PCR techniques are suitable for the characterisation of viremia   |
| 318 | kinetics in plasma and serum samples. Knowledge of SARS-CoV-2 kinetics in blood allows            |
| 319 | stratification of hospitalised COVID-19 patients.   |
| 320 |   |
| 321 | Author contributions.   |
| 322 | Credit authorship contribution statement  |
| 323 | N. D. Zurita Cruz: methodology, formal analysis, investigation, writing.                          |
| 324 | A. Martín Ramírez: methodology, formal analysis, investigation, writing.                          |
| 325 | D. A. Rodríguez Serrano: resources, writing.  |
| 326 | I. González Álvaro: resources, writing.   |
| 327 | E. Roy Vallejo: resources, writing.   |
| 328 | R. de la Cámara: resources, writing.  |
| 329 | L. Fontán García-Rodrigo: methodology, formal analysis, writing.                                  |
| 330 | L. Cardeñoso Domingo: conceptualization, investigation, methodology, writing, supervision.        |
| 331 | All the authors have revised and approved the final version of the manuscript                     |
| 332 |   |
| 333 | Funding   |
| 334 | This research did not receive any specific grant from funding agencies in the public, commercial, |
| 335 | or not-for-profit sectors.  |
| 336 | The work of ER-V has been funded by a Rio-Hortega grant CM19/00149 from the Ministerio de         |
| 337 | Economía y Competitividad (Instituto de Salud Carlos III) and co-funded by The European           |
| 338 | Regional Development Fund (ERDF) "A way to make Europe"   |

## 340 Declaration of Competing Interest

| 341 | The    | authors | declare   | that  | they  | have    | no    | known   | competing    | financial   | interests  | or | personal |
|-----|--------|---------|-----------|-------|-------|---------|-------|---------|--------------|-------------|------------|----|----------|
| 342 | relati | onships | that coul | d hav | e app | eared t | to in | fluence | the work rep | orted in th | nis paper. |    |          |

343

## 344 Acknowledgments

- 345 Special thanks to our patients and relatives for agreeing with the use of pseudonymized clinical
- data and surpluses of clinical samples to perform this study, to Manuel Gomez Gutierrez, PhD for
- 347 his excellent editing assistance, and Ancor Sanz for assistance with statistical analysis.
- 348 PREINMUN-COVID group includes:
- 349 Anesthesiology: Rosa Méndez, Julia Hernando, David Arribas.
- 350 **Hematology:** Javier Ortiz, Isabel Iturrate, Rafael de la Cámara.
- 351 Immunology: Francisco Sánchez-Madrid, Ildefonso Sánchez-Cerrillo, Pedro Martínez-Fleta,
- 352 Celia López-Sanz, Ligia Gabrie, Luciana del Campo Guerola, Elena Fernández, Reyes Tejedor,
- 353 Cecilia Muñoz, Aranzazu Alfranca. Ana Triguero-Martínez.
- 354 Intensive Care Unit: Marta Chicot Llano, Pablo Patiño Haro, Marina Trigueros Genao, Begoña
- 355 Quicios, Begoña González, Diego Aníbal Rodríguez Serrano.

356 Internal Medicine-Infectious Diseases: Emilia Roy-Vallejo, Eduardo Sánchez, Fernando
357 Moldenhauer, Marianela Ciudad, Ana Barrios, Beatriz Sánchez, Almudena Villa, Jesús Álvarez,

- 358 Cristina Arévalo Román, José María Galván-Román, Jesús Sanz, Carmen Suárez Fernández.
- 359 Microbiology: Nelly Daniela Zurita, Diego Domingo García, Teresa Alarcón Cavero, María
- 360 Auxiliadora Semiglia Chong, Ainhoa Gutiérrez Cobos, María Diez Aguilar, Isabel García Arata,

361 Laura Cardeñoso Domingo.

| 362 | Pneumology: Elena Ávalos, Celeste Marcos, Elena García Castillo, Ana Sánchez Azofra, Tamara     |
|-----|---|
| 363 | Alonso, Carolina Cisneros, Claudia Valenzuela, Francisco Javier García Pérez, Rosa María Girón, |
| 364 | Javier Aspa, Enrique Zamora, Mar Barrio Mayo, Rosalina Henares Espi, Olga Rajas, Joan B.        |
| 365 | Soriano, Julio Ancochea.  |
|     |   |

366

- 367 References
- Cheng ZJ, Shan J. 2020. 2019 Novel coronavirus: where we are and what we know.
   Infection 48:155–163.
- WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard
   with Vaccination Data. https://covid19.who.int/. Retrieved 30 June 2021.
- Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby
   DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello
   AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel
   ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. 2020. Presenting
   Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with
   COVID-19 in the New York City Area. JAMA Journal of the American Medical Association
   323:2052–2059.
- Asghar MS, Kazmi SJH, Khan NA, Akram M, Hassan M, Rasheed U, Khan SA. 2020. Poor
   Prognostic Biochemical Markers Predicting Fatalities Caused by COVID-19: A
   Retrospective Observational Study from a Developing Country. Cureus 12.
- Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, Ye C, Zhang P, Xing
   Y, Guo H, Tang W. 2020. Risk factors of critical & mortal COVID-19 cases: A systematic
   literature review and meta-analysis. Journal of Infection. W.B. Saunders Ltd
   https://doi.org/10.1016/j.jinf.2020.04.021.

Li F, Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B, Ding J,
 Li F. 2020. Clinical Infectious Diseases Detectable Serum Severe Acute Respiratory
 Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated with Drastically
 Elevated Interleukin 6 Level in Critically III Patients With Coronavirus Disease 2019.
 Clinical Infectious Diseases <sup>®</sup> 71:1937–1979.

- 391 7. del Rio C, Malani PN. 2020. COVID-19 New Insights on a Rapidly Changing Epidemic.
   392 JAMA Journal of the American Medical Association. American Medical Association
   393 https://doi.org/10.1001/jama.2020.3072.
- Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, Park SY, Son HJ, Yu S, Park JW, Choo EJ, Park S,
   Loeb M, Kim TH. 2020. Clinical Course and Molecular Viral Shedding among
   Asymptomatic and Symptomatic Patients with SARS-CoV-2 Infection in a Community
   Treatment Center in the Republic of Korea. JAMA Internal Medicine 180:1447–1452.
- Tan C, Li S, Liang Y, Chen M, Liu J. 2020. SARS-CoV-2 viremia may predict rapid
   deterioration of COVID-19 patients. Brazilian Journal of Infectious Diseases 24:565–569.
- Eberhardt KA, Meyer-Schwickerath C, Heger E, Knops E, Lehmann C, Rybniker J,
  Schommers P, Eichenauer DA, Kurth F, Ramharter M, Kaiser R, Holtick U, Klein F, Jung N,
  Cristanziano V di. 2020. RNAemia Corresponds to Disease Severity and Antibody
  Response in Hospitalized COVID-19 Patients. Viruses 12.
- Hagman K, Hedenstierna M, Gille-Johnson P, Hammas B, Grabbe M, Dillner J, Ursing J.
  2020. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a
  retrospective cohort study. Clinical Infectious Diseases
  https://doi.org/doi:10.1093/cid/ciaa1285.
- 408 12. Xu D, Zhou F, Sun W, Chen L, Lan L, Li H, Xiao F, Li Y, Kolachalama VB, Li Y, Wang X, Xu H.
  409 2020. Relationship Between Serum Severe Acute Respiratory Syndrome Coronavirus 2

410 Nucleic Acid and Organ Damage in Coronavirus 2019 Patients: A Cohort Study. Clinical
411 Infectious Diseases https://doi.org/10.1093/cid/ciaa1085.

- 412 13. Rodríguez-Serrano DA, Roy-Vallejo E, Zurita Cruz ND, Martín Ramírez A, Rodríguez-García
- 413 SC, Arevalillo-Fernández N, Galván-Román JM, Fontán García-Rodrigo L, Vega-Piris L,
- 414 Chicot Llano M, Arribas Méndez D, González de Marcos B, Hernando Santos J, Sánchez
- 415 Azofra A, Ávalos Pérez-Urria E, Rodriguez-Cortes P, Esparcia L, Marcos-Jimenez A,
- 416 Sánchez-Alonso S, Llorente I, Soriano J, Suárez Fernández C, García-Vicuña R, Ancochea
- 417 J, Sanz J, Muñoz-Calleja C, de la Cámara R, Canabal Berlanga A, González-Álvaro I,
- 418 Cardeñoso L. 2021. Detection of SARS-CoV-2 RNA in serum is associated with increased
- 419 mortality risk in hospitalized COVID-19 patients. Scientific Reports 11:13134.
- 420 14. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D,
  421 Rennie D, Korevaar DA, ré mie Cohen JF. 2015. STARD 2015: An Updated List of Essential

422 Items for Reporting Diagnostic Accuracy Studies. British medical journal 351.

- 423 15. ThermoFisher Scientific. 2015. QuantStudio Design and Analysis desktop Software User
  424 Guide. (Pub. no. MAN0010408) Revision B.0.
- Martín Ramírez A, Zurita Cruz ND, Gutiérrez-Cobos A, Rodríguez Serrano DA, González
  Álvaro I, Roy Vallejo E, Gómez de Frutos S, Fontán García-Rodrigo L, Cardeñoso Domingo
  L. 2022. Evaluation of two RT-PCR techniques for SARS-CoV-2 RNA detection in serum for
  microbiological diagnosis. Journal of Virological Methods 300:114411.
- Heinrich F, Nentwich MF, Bibiza-Freiwald E, Nörz D, Roedl K, Christner M, Hoffmann A,
  Olearo F, Kluge S, Aepfelbacher M, Wichmann D, Lütgehetmann M, Pfefferle S. Blood
  SARS-CoV-2 RNA Load Predicts Outcome OFID 1 SARS-CoV-2 Blood RNA Load Predicts
  Outcome in Critically III COVID-19 Patients https://doi.org/10.1093/ofid/ofab509.

- 433 18. Chen L, Wang G, Long X, Hou H, Wei J, Cao Y, Tan J, Liu W, Huang L, Meng F, Huang L,
  434 Wang N, Zhao J, Huang G, Sun Z, Wang W, Zhou J. 2021. Dynamics of Blood Viral Load Is
  435 Strongly Associated with Clinical Outcomes in Coronavirus Disease 2019 (COVID-19)
  436 Patients. The Journal of Molecular Diagnostics 23:10–18.
- 437 19. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, Xie G, Lin S, Wang R, Yang X, Chen W, Wang Q,
  438 Zhang D, Liu Y, Gong R, Ma Z, Lu S, Xiao Y, Gu Y, Zhang J, Yao H, Xu K, Lu X, Wei G, Zhou J,
  439 Fang Q, Cai H, Qiu Y, Sheng J, Chen Y, Liang T. 2020. Viral load dynamics and disease
  440 severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March
  441 2020: retrospective cohort study. BMJ 369.
- 442 20. Agarwal J, Singh V, Garg J, Karoli R, Tiwari S, Naqvi S, Das A, Sen M. 2021. RNAemia and
  443 Clinical Outcome in COVID-19 Patients. Journal of Microbiology and Infectious Diseases J
  444 Microbiol Infect Dis 11:116–123.
- Colagrossi L, Antonello M, Renica S, Merli M, Matarazzo E, Travi G, Vecchi M, Colombo J,
  Muscatello A, Grasselli G, Molteni SN, Scaravilli V, Cattaneo E, Fanti D, Vismara C,
  Bandera A, Gori A, Puoti M, Cento V, Alteri C, Perno CF. SARS-CoV-2 RNA in plasma
  samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study
  https://doi.org/10.1186/s12879-021-05886-2.
- 450 22. Hogan CA, Stevens BA, Sahoo MK, Huang C, Garamani N, Gombar S, Yamamoto F, 451 Murugesan K, Kurzer J, Zehnder J, Pinsky BA. Clinical Infectious Diseases High Frequency 452 of SARS-CoV-2 **RNAemia** and Association with Severe Disease https://doi.org/10.1093/cid/ciaa1054. 453
- Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, Worrall D, Giguel F,
  Piechocka-Trocha A, Atyeo C, Fischinger S, Chan A, Flaherty KT, Hall K, Dougan M, Ryan
  ET, Gillespie E, Chishti R, Li Y, Jilg N, Hanidziar D, Baron RM, Baden L, Tsibris AM,
  Armstrong KA, Kuritzkes DR, Alter G, Walker BD, Yu X, Li JZ. 2020. SARS-CoV-2 viral load

458 is associated with increased disease severity and mortality. Nature communications459 11:5493-.

- 460 24. Jacobs JL, Mellors JW. Detection of Severe Acute Respiratory Syndrome Coronavirus 2
  461 (SARS-CoV-2) RNA in Blood of Patients with Coronavirus Disease 2019 (COVID-19): What
- 462 Does It Mean? https://doi.org/10.1093/cid/ciaa1316.
- Santos Bravo M, Nicolás D, Berengua C, Fernandez M, Hurtado JC, Tortajada M, Barroso
  S, Vilella A, Mosquera MM, Vila J, Marcos MA. 2021. The Journal of Infectious Diseases
  Severe Acute Respiratory Syndrome Coronavirus 2 Normalized Viral Loads and
  Subgenomic RNA Detection as Tools for Improving Clinical Decision Making and Work
  Reincorporation. The Journal of Infectious Diseases <sup>®</sup> 224:1325–1357.
- Berger A, Braner J, Doerr HW, Weber B. 1998. Quantification of Viral Load: Clinical
  Relevance for Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus
  Infection. Intervirology 41:24–34.
- 471 27. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. 2000.
  472 Standardization of Hepatitis C Virus RNA Quantification. Hepatology 32:654–659.
- 473 28. Peter JB, Sevall JS. 2004. Molecular-Based Methods for Quantifying HIV Viral Load.
  474 https://home.liebertpub.com/apc 18:75–79.
- 475 29. Guiver M, Fox AJ, Mutton K, Mogulkoc N, Egan J. 2001. Evaluation of CMV viral load using
  476 TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung
  477 transplant recipients. Transplantation 71:1609–1615.
- 478 30. Xu D, Zhou F, Sun W, Chen L, Lan L, Li H, Xiao F, Li Y, Kolachalama VB, Li Y, Wang X, Xu H.
- 2021. Relationship Between Serum Severe Acute Respiratory Syndrome Coronavirus 2
  Nucleic Acid and Organ Damage in Coronavirus 2019 Patients: A Cohort Study. Clinical
  Infectious Diseases 73:68–75.

482 31. Veyer D, Kernéis S, Poulet G, Wack M, Robillard N, Taly V, L'Honneur A-S, Rozenberg F, 483 Laurent-Puig P, Bélec L, Hadjadj J, Terrier B, Péré H. 2020. Highly Sensitive Quantification 484 of Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Sheds Light on its 485 Potential Clinical Value. Clinical Infectious Diseases https://doi.org/10.1093/cid/ciaa1196. 486

487 Jacobs JL, Bain W, Naqvi A, Staines B, Castanha PMS, Yang H, Boltz VF, Barratt-Boyes S, 32. 488 Margues ETA, Mitchell SL, Methé B, Olonisakin TF, Haidar G, Burke TW, Petzold E, Denny 489 T, Woods CW, Mcverry BJ, Lee JS, Watkins SC, St Croix CM, Morris A, Kearney MF, 490 Ladinsky MS, Bjorkman PJ, Kitsios G, Mellors JW. SARS-CoV-2 Viremia is Associated with 491 COVID-19 Clinical Outcomes Severity and Predicts 492 https://doi.org/10.1093/cid/ciab686/6347519.

493 33. Peña KB, Riu F, Gumà J, Guilarte C, Pique B, Hernandez A, Àvila A, Parra S, Castro A, Rovira
494 C, Cueto P, Vallverdu I, Parada D. 2021. Study of the Plasma and Buffy Coat in Patients
495 with SARS-CoV-2 Infection-A Preliminary Report Academic Editors: Natalia Rakislova and
496 Jaume Ordi https://doi.org/10.3390/pathogens10070805.